Katya Nikolova Todorova

Prof. Katya Nikolova Todorova

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2025 in COVID
Verified
Journal Article
Open access
PDF file
VTVictoria Tsvetanova Tsvetkova
Victoria Tsvetanova Tsvetkova
MTMalvina Todorova
Malvina Todorova
MAMilena Atanasova
Milena Atanasova
IGIrena Gencheva
Irena Gencheva
KTKatya Nikolova Todorova
Katya Nikolova Todorova
Introduction: Immune dysfunction plays a significant role in Metabolic syndrome, contributing to both insulin resistance and chronic low-grade inflammation. This immune dysfunction is characterized by overproduction of inflammatory cytokines among which of primary importance are tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and (MCP-1), whereas others such as interferon gamma (IFN-γ), IL-17A, and the anti-inflammatory IL-10 appear to be of secondary importance. Cytokines also play a significant role in Post-COVID disorders contributing to prolonged immune dysregulation and persistent subclinical inflammation. However, their role in the newly emerging metabolic disorders following infection remains poorly defined. Methods and materials: In the current study 78 patients (26 men and 52 women) were included, divided into two groups—group 1 (individuals with newly diagnosed carbohydrate disorders after proven COVID-19 or Post-COVID group; n = 35) and group 2 (COVID-19 negative persons with Metabolic Syndrome; n = 33). They were further divided into several subgroups according to type of metabolic disorder present. Standard biochemical, hormonal and immunological parameters were measured using ELISA and ECLIA methods, as well as some indices for assessment of insulin resistance were calculated using the corresponding formula. Results: Patients from both groups demonstrate similar metabolic parameters including BMI and unadjusted lipid and uric acid levels (p > 0.05). After adjustment for age, sex, and BMI revealed significant differences, Post-COVID status independently predicted higher fasting glucose, HbA1c, total cholesterol, LDL-cholesterol, triglycerides, uric acid, and insulin-resistance indices, indicating substantially impaired glycemic and metabolic control beyond traditional risk factors. Furthermore, the Post-COVID cohort demonstrated marked cytokine dysregulation, with significantly elevated levels of TNF-α, IFN-γ, IL-17A, and IL-10 after adjustment. Conclusions: The observed changes in both metabolic and immune parameters studied among the two groups show many similarities, but some significant differences have also been identified. Together, these findings indicate that Post-COVID metabolic dysfunction is characterized by inflammation-driven dyslipidemia, heightened oxidative stress, and persistent immune activation, distinguishing it from classical Metabolic syndrome.

8 December 2025 in Journal of Biomedical and Clinical Research
Verified
Journal Article
Open access
VTVictoria Tsvetanova Tsvetkova
Victoria Tsvetanova Tsvetkova
MTMalvina Todorova
Malvina Todorova
KTKatya Nikolova Todorova
Katya Nikolova Todorova
MAMilena Atanasova
Milena Atanasova
IGIrena Gencheva
Irena Gencheva
Background: It is now proven that insulin resistance occurring during SARS-CoV-2 infection is the major cause for the hyperglycemia observed, and it can even persist long after recovery. The precise mechanisms of insulin resistance, whether new-onset or pre-existing, remain largely a mystery. Chronic immune dysregulation, persistent subclinical inflammation, adipose tissue dysfunction and pro-inflammatory cytokines are thought to be of fundamental importance. The current study aims to investigate the role of SARS-CoV-2 infection and the related inflammation in the pathogenesis of insulin resistance in different types of newly emerging disorders of carbohydrate metabolism following infection. Methods and materials: The current study included 168 patients (59 males and 109 women; mean age 54.04 ± 8.08 years), divided into three groups: group 1 (patients with active COVID-19 infection; n = 100), group 2 (individuals with newly diagnosed carbohydrate disorders after proven COVID-19 or post-COVID group; n = 35) and group 3 (COVID-19 negative subjects with Metabolic Syndrome; n = 33). Standard biochemical and immunological parameters were measured, and atherogenic indices for IR (TyG index and TG/HDL-C ratio) were calculated using the corresponding formula. Results: Patients with active coronavirus infection demonstrated the highest levels of TyG index and TG/HDL-C ratio, which differed significantly from both the reference COVID-negative group and from the Post-COVID group (p < 0.05). Among the individuals in the post-COVID group, we found a positive correlation between TyG index and IL-10 (r = 0.481; p = 0.008), IL-17A (r = 0.384; p = 0.048) and HCF-D (r = 0.387; p = 0.038). In the same group, the TG/HDL-C ratio positively correlated with CD8 (r = 0.648; p < 0.001), TNF-α (r = 0.559; p < 0.001), IL-10 (r = 0.954; p < 0.001), 8-Epi-PGF2α (r = 0.451; p = 0.006) and HIF-1α (r = 0.863; p < 0.001). Conclusion: Immune dysregulation, along with oxidative stress and cellular hypoxia observed during and after infection, seems to be implicated in the genesis, maintenance and progression of the insulin resistance (IR). IR, as measured by widely used atherogenic indices, is present not only during the COVID-19 course but also in cases of newly emerging carbohydrate disorders following infection, including T2DM, prediabetes, and T1DM.

6 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
VTVictoria Tsvetanova Tsvetkova
Victoria Tsvetanova Tsvetkova
MTMalvina Todorova
Malvina Todorova
MAMilena Atanasova
Milena Atanasova
IGIrena Gencheva
Irena Gencheva
KTKatya Nikolova Todorova
Katya Nikolova Todorova
Introduction: Immune dysfunction plays a significant role in metabolic syndrome, contributing to both IR and chronic low-grade inflammation. This immune dysfunc-tion is characterized by overproduction of inflammatory cytokines among which of primary importance are tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and MCP-1, whereas others such as IFN-γ, IL-17А, and the anti-inflammatory IL-10 appear to be of secondary importance. Cytokines also play a significant role in post-COVID disorders contributing to prolonged immune dysregulation and persistent subclinical inflammation. However, their role in the newly emerging metabolic disorders follow-ing infection remains poorly defined. Methods and materials: In the current study 78 patients (26 men and 52 women) were included, divided into two groups - group 1 (individuals with newly diagnosed car-bohydrate disorders after proven COVID-19 or post-COVID group; n=35) and group 2 (COVID-19 negative persons with Metabolic Syndrome; n=33). They were further di-vided into several subgroups according to type of metabolic disorder present. Standard biochemical, hormonal and immunological parameters were measured using ELISA and ECLIA methods, as wells as some indices for assessment of insulin resistance were calculated using the corresponding formula. Results: Patients from both groups demonstrate similar (P>0.05) metabolic parameters including BMI, lipid profile, uric acid, whereas those from the Post-COVID group demonstrated poor glycaemic parameters (Fasting plasma glucose and HbA1c) (P< 0.05). Patients from both Post-COVID and COVID-negative group demonstrated high levels of IR, the latter having higher mean values of both indices. Higher TNF-α and IL-10 values were registered in the Post-COVID group (P>0.05) whereas higher levels of INF-γ (P< 0.001) and IL-17A we registered in the COVID-negative group (P>0.05). A lot of correlations were found between the immunological parameters evaluated and the metabolic ones. Conclusion: The observed changes in both metabolic and immune parameters studied among the two groups show many similarities, but some significant differences have also been identified. What can be asserted is that cytokines definitely have an im-portant role in Post-COVID newly-emerging metabolic disorders contributing to both adipose tissue dysfunction, IR, dysglycaemia and dyslipidemia observed.

13 February 2019
Verified
Book Chapter
Open access
PDF file
MGMariana Petrova Genova
Mariana Petrova Genova
BABisera Dimitrova Atanasova
Bisera Dimitrova Atanasova
KTKatya Nikolova Todorova
Katya Nikolova Todorova
Pregnancy is a complex of metabolic, physiological, biochemical, and immunological changes in women’s body, usually reversible after delivery in normal pregnancy. Gestational diabetes mellitus (GDM) is defined as “any degree of glucose intolerance with onset or first recognition during the current pregnancy.” The etiology of the GDM is multifactorial and not sufficiently elucidated. The overweight and obesity during prepregnancy and pregnancy are one of the main modifiable risk factors of GDM. Maternal obesity increases the risk of a number of pregnancy complications, adverse pregnancy outcome for mother and child, and related chronic conditions in women. The obesity prevalence is the greatest among children of obese mothers, and an independent association between maternal body mass index and offspring adiposity and insulin resistance exists. Although the underlying mechanism remains unclear, available evidence suggests that GDM pathogenesis is based on relatively diminished insulin secretion coupled with pregnancy-induced insulin resistance. Recent findings provide data that higher BMI leads to decreased insulin sensitivity and higher degree of insulin resistance and contributes to GDM development.

13 March 2026 in COVID
Verified
Journal Article
Open access
PDF file
MTMalvina Svilenova Todorova
Malvina Svilenova Todorova
VTVictoria Tsvetanova Tsvetkova
Victoria Tsvetanova Tsvetkova
MAMilena Atanasova
Milena Atanasova
ARAdelaida Ruseva
Adelaida Ruseva
KTKatya Nikolova Todorova
Katya Nikolova Todorova
Coronavirus disease 2019 (COVID-19) is associated with systemic inflammation and immune dysregulation, potentially affecting hypothalamic–pituitary–adrenal (HPA) axis function and glucocorticoid signaling. However, the dynamics and clinical relevance of these alterations across different disease phases remain insufficiently defined. In this cross-sectional observational study, 101 participants were divided into three groups: patients with active COVID-19 (n = 33), individuals ≥ 6 months post-COVID-19 (n = 35), and a reference group of healthy individuals (n = 33). Serum cortisol, circulating glucocorticoid receptor alpha (GRα), and selected cytokines were measured. Statistical analysis included parametric and non-parametric tests, multivariable generalized linear models adjusted for age and sex, correlation analysis, and receiver operating characteristic (ROC) analysis. Lower serum cortisol levels were observed in approximately two-thirds of patients during the acute phase. Circulating GRα concentrations demonstrated a significant gradient across groups, with the lowest levels in active infection and partial restoration post-COVID. Active COVID-19 status remained independently associated with reduced GRα levels after adjustment for age and sex. The cytokine profile, including interleukin-17A (IL-17A), tumor necrosis factor-alpha (TNF-α), and interleukin-10 (IL-10), provided a mechanistic context for inflammation-associated modulation of glucocorticoid signaling, most evident during acute infection. Significant correlations between cortisol, GRα, and inflammatory mediators were observed only in this phase. ROC analysis demonstrated a high degree of statistical separation between active COVID-19 and healthy individuals (AUC 0.942; 95% CI: 0.878–1.000). Given the predefined group structure and modest sample size, these findings should be considered exploratory. Overall, the results support the presence of dynamic and potentially reversible immune–endocrine dysregulation during and after SARS-CoV-2 infection. Further validation in larger prospective cohorts is required.

2 April 2026 in Diabetology
Verified
Journal Article
Open access
PDF file
VTVictoria Tsvetanova Tsvetkova
Victoria Tsvetanova Tsvetkova
MTMalvina Svilenova Todorova
Malvina Svilenova Todorova
MAMilena Atanasova
Milena Atanasova
IGIrena Gencheva
Irena Gencheva
KTKatya Nikolova Todorova
Katya Nikolova Todorova
Aims/hypothesis: Hypoxia and oxidative stress have been implicated in both metabolic syndrome and COVID-19-associated dysglycaemia, yet it remains unclear whether shared or distinct mechanisms underlie β-cell dysfunction across these conditions. We investigated hypoxia- and oxidative stress-related pathways in relation to β-cell function during acute COVID-19, post-COVID metabolic states, and COVID-negative metabolic syndrome. Methods: In this prospective observational study, 100 adults were stratified into three groups: active COVID-19 (n = 32), post-COVID with newly diagnosed carbohydrate metabolism disorders (n = 35), and COVID-negative individuals with metabolic syndrome (n = 33). Circulating markers of hypoxia (HIF-1α), oxidative stress (8-epi-prostaglandin F2α), and antioxidant response (NFE2L2) were measured alongside α- and β-cell functional markers, including C-peptide, proinsulin, glucagon, and derived indices of β-cell processing and secretory efficiency. Non-parametric statistical analyses were applied. Results: Circulating HIF-1α levels differed significantly across study groups (p < 0.001), with the highest concentrations observed during active COVID-19, intermediate levels in COVID-negative individuals with metabolic syndrome, and the lowest levels in the post-COVID group. In contrast, oxidative stress, assessed by 8-epi-prostaglandin F2α, differed significantly across groups (p < 0.001), increasing from acute COVID-19 to post-COVID and reaching the highest levels in metabolic syndrome; however, the difference between the post-COVID and metabolic syndrome groups did not remain significant after correction for multiple testing. NFE2L2 concentrations did not differ significantly between groups. Marked β-cell dysfunction was observed predominantly in COVID-negative individuals with metabolic syndrome, characterized by reduced C-peptide levels, elevated glucagon concentrations, increased proinsulin/C-peptide ratios, and reduced C-peptide/glucose ratios (all overall group comparisons p < 0.001). In contrast, β-cell secretory indices were relatively preserved during acute and post-COVID states despite pronounced alterations in hypoxia and oxidative stress markers. Conclusions/interpretation: Hypoxia- and oxidative stress-related pathways exhibit distinct, context-dependent patterns across acute COVID-19, post-COVID dysglycaemia, and metabolic syndrome. Acute COVID-19 is characterized by pronounced hypoxia signalling with relative preservation of β-cell function, whereas chronic metabolic syndrome is associated with sustained oxidative stress and impaired β-cell processing and secretory efficiency. These findings suggest that diabetes-related β-cell dysfunction is more closely associated with chronic oxidative and metabolic stress than with transient infection-related hypoxia during SARS-CoV-2 infection.